EPHA2, a promising therapeutic target for hepatocellular carcinoma

被引：7
|
作者：
Wang, Hao
Qiu, Wei [1 ]
机构：
[1] Loyola Univ Chicago, Stritch Sch Med, Dept Surg, Maywood, IL 60153 USA
来源：
MOLECULAR & CELLULAR ONCOLOGY | 2021年 / 8卷 / 03期
基金：
美国国家卫生研究院;
关键词：
EPHA2; HCC; AKT; STAT3; JAK1; INHIBITION; RECEPTOR; LIGAND;
D O I：
10.1080/23723556.2021.1910009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Identifying critical drivers of oncogenesis and tumor progression is essential for developing effective hepatocellular carcinoma (HCC) therapeutics. Our recent findings has demonstrated that targeting Ephrin Receptor A2 (EPHA2) suppresses HCC initiation and progression by dual inhibition of the Protein Kinase B (AKT) and Signal Transducer and Activator of Transcription 3 (STAT3) signaling.
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Dual targeting of EphA2 and FAK in ovarian carcinoma
    Shahzad, Mian
    Lu, Chunhua
    Lee, Jong-Wong
    Danes, Christopher
    Mangala, Lingegowda
    Haider, Jyotsnabaran
    Nick, Alpa
    Stone, Rebecca
    Kim, Hey-Sun
    Nam, Eun Ji
    Mora, Edna
    Landen, Charles
    Coleman, Robert
    Lopez-Berestein, Gabiel
    Sood, Anil
    CANCER RESEARCH, 2009, 69
  • [32] THE TYROSINE KINASE RECEPTOR EPHA2 IS A DRUG TARGET FOR OSTEOARTHRITIS
    Ferrao Blanco, M. N.
    Bastiaansen-Jenniskens, Y. M.
    Narcisi, R.
    Chambers, M. G.
    Pitsillides, A. A.
    van Osch, G. J.
    OSTEOARTHRITIS AND CARTILAGE, 2020, 28 : S36 - S37
  • [33] EphA2 as a novel molecular marker and target in glioblastoma multiforme
    Wykosky, J
    Gibo, DM
    Stanton, C
    Debinski, W
    MOLECULAR CANCER RESEARCH, 2005, 3 (10) : 541 - 551
  • [34] COE Inhibits Vasculogenic Mimicry by Targeting EphA2 in Hepatocellular Carcinoma, a Research Based on Proteomics Analysis
    Chu, Zewen
    Shi, Xin
    Chen, Gaoyang
    He, Xuejun
    Qian, Yayun
    Wang, Haibo
    Tao, Li
    Liu, Yanqing
    Jiang, Wei
    Chen, Jue
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [35] RETRACTED ARTICLE: EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma
    Mark S Duxbury
    Hiromichi Ito
    Michael J Zinner
    Stanley W Ashley
    Edward E Whang
    Oncogene, 2004, 23 : 1448 - 1456
  • [36] Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma
    Wu, Xiong-Zhi
    Xie, Guang-Ru
    Chen, Dan
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 (08) : 1178 - 1182
  • [37] Evaluation of EphA2 as a therapeutic target for redirected T-cell killing by DART® bispecific molecules
    Fieger, Claudia B.
    Shah, Kalpana
    Chichili, Gurunadh
    Li, Jonathan
    Son, Thomas
    Hooley, Jeffrey
    Chen, Francine
    Gorlatov, Sergey
    Burke, Steve
    Ciccarone, Valentina
    Alderson, Ralph
    Loo, Deryk
    Johnson, Syd
    Bonvini, Ezio
    Moore, Paul
    CANCER RESEARCH, 2016, 76
  • [38] Retraction Note: EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma
    Mark S. Duxbury
    Hiromichi Ito
    Michael J. Zinner
    Stanley W. Ashley
    Edward E. Whang
    Oncogene, 2023, 42 : 938 - 938
  • [39] Unveiling the therapeutic promise of EphA2 in glioblastoma: a comprehensive review
    Qiu, Caohang
    Sun, Ning
    Zeng, Shan
    Chen, Ligang
    Gong, Feilong
    Tian, Junjie
    Xiong, Yu
    Peng, Lilei
    He, Haiping
    Ming, Yang
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [40] EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma
    Gai, Qu-Jing
    Fu, Zhen
    He, Jiang
    Mao, Min
    Yao, Xiao-Xue
    Qin, Yan
    Lan, Xi
    Zhang, Lin
    Miao, Jing-Ya
    Wang, Yan-Xia
    Zhu, Jiang
    Yang, Fei-Cheng
    Lu, Hui-Min
    Yan, Ze-Xuan
    Chen, Fang-Lin
    Shi, Yu
    Ping, Yi-Fang
    Cui, You-Hong
    Zhang, Xia
    Liu, Xindong
    Yao, Xiao-Hong
    Lv, Sheng-Qing
    Bian, Xiu-Wu
    Wang, Yan
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2022, 7 (01)
12345